Advocacy Archives – Page 8 of 11 – Treatment Action Group

Unique Barriers to COVID-19 Vaccine Access for Black Communities

May 11, 2021
Dorrit Walsh

On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times

May 10, 2021
Dorrit Walsh

This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.

Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics

April 1, 2021
Dorrit Walsh

TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.

Open Letter: Urgent Action Necessary to Improve Equitable Access to GeneXpert TB Diagnostics and Achieve 1/4/6×24

February 2, 2021
Dorrit Walsh

A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...

US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic

December 11, 2020
Dorrit Walsh

Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.

TAG Applauds Dr. Demetre Daskalakis’ Appointment as CDC Director of the Division of HIV/AIDS Prevention: NYC’s Loss is America’s Gain

November 19, 2020
Dorrit Walsh

Treatment Action Group applauds the appointment of Dr. Demetre Daskalakis to helm the U.S. Centers for Disease Control and Prevention (CDC)’s Division of HIV/AIDS Prevention (DHAP). We can think of no better public health practitioner to embody true innovation and disrupt the status quo in our national HIV prevention response.

COVID-19 and Impacted Communities: A Media Communications Guide

November 12, 2020
Dorrit Walsh

This easy-to-use guide is designed to provide journalists and communication professionals the tools needed to ensure accurate reporting and curb any related stigma associated with the novel coronavirus SARS-COV-2, also known and reported as COVID-19. We invite you to use this to inform your own writing and to share it with colleagues and cohorts that work in media and communications.

Letter to Special Rapporteur on Cultural Rights

November 9, 2020
Dorrit Walsh

Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her forthcoming communication with the United Nations General Assembly on COVID-19.

Treatment Action Group Mourns the Loss of Timothy Ray Brown

September 30, 2020
Dorrit Walsh

Treatment Action Group (TAG) is profoundly saddened by the news that Timothy Ray Brown—the first person in the world considered cured of HIV infection—died yesterday from a recurrence of cancer.

New York Increases Access to Hepatitis C Treatment for Medicaid Patients

September 21, 2020
Dorrit Walsh

The National Viral Hepatitis Roundtable (NVHR), the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI), and the Treatment Action Group (TAG) today applauded New York State (NYS) Medicaid for removing the requirement that new patients receive prior authorization approval for hepatitis C treatment.